Cyclerion and Korsana announce $380 million merger deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices jump after Trump threatens to hit Iran 'very hard'
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- Hershey appoints State Farm executive Joe Park to board of directors
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
April 1, 2026 7:05 AM EDTCombined company to operate as Korsana Biosciences and to advance Korsanas potential best-in-class therapeutics to treat neurodegenerative diseases
Korsanas lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimers disease
Concurrent private financing of approximately $380 million expected to fund Korsanas operations into 2029, including multiple clinical trial data readouts expected in 2027
Conference call scheduled for April 1, 2026, at 8:00 am ET
WALTHAM, Mass.--(BUSINESS WIRE)-- Cyclerion Therapeutics, Inc. (Cyclerion) (Nasdaq: CYCN) and... More
